estropipate, Ogen

  • Pharmacy Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Medical and Pharmacy Editor: Jay W. Marks, MD
    Jay W. Marks, MD

    Jay W. Marks, MD

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

  • Medical and Pharmacy Editor: Charles Patrick Davis, MD, PhD
    Charles Patrick Davis, MD, PhD

    Charles Patrick Davis, MD, PhD

    Dr. Charles "Pat" Davis, MD, PhD, is a board certified Emergency Medicine doctor who currently practices as a consultant and staff member for hospitals. He has a PhD in Microbiology (UT at Austin), and the MD (Univ. Texas Medical Branch, Galveston). He is a Clinical Professor (retired) in the Division of Emergency Medicine, UT Health Science Center at San Antonio, and has been the Chief of Emergency Medicine at UT Medical Branch and at UTHSCSA with over 250 publications.

GENERIC NAME: estropipate


DRUG CLASS AND MECHANISM: Estropipate is a crystalline form of estrone, a form of estrogen. Estrogens occur in nature in several forms. In women with active menstrual cycles, the ovaries produce between 70 and 500 micrograms of one estrogen form, estradiol, daily. The estradiol is converted to estrone and to a lesser extent, estriol. After menopause, estrone is the most active circulating estrogen but is then is produced by the adrenal glands. Estrogens cause growth and development of female sex organs and maintains sexual characteristics, including underarm and pubic hair and the shape of body contours and the strength of bones. They increase secretions from the cervix and growth of the inner lining of the uterus (endometrium). They also reduce LDL-cholesterol ("bad" cholesterol) and increase HDL-cholesterol ("good" cholesterol) concentrations in the blood. Estrogens, when taken alone or in combination with a progestin, have been shown to reduce the risk for hip fractures due to osteoporosis by 25%. The FDA approved estropipate in June 1977.



PREPARATIONS: Tablets: 0.75, 1.5, 3, and 6 mg or 0.625, 1.25 or 2.5, depending on the drug manufacturer.

STORAGE: Tablets should be stored below 25 C (77 F).

PRESCRIBED FOR: Estropipate is prescribed for treatment of symptoms associated with menopause (hot flashes, vaginal dryness), prevention of bone fractures associated with osteoporosis, low estrogen levels, and dysfunctional (excessive and painful) uterine bleeding.

Quick GuideMenopause & Perimenopause: Symptoms, Signs

Menopause & Perimenopause: Symptoms, Signs
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

See more info: estropipate on RxList
RxList Logo

Need help identifying pills and medications?

Use the pill identifier tool on RxList.

Subscribe to MedicineNet's Women's Health Newsletter

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors